Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06024603 | RECRUITING | Refractory Cancer

Individualized Treatments in Adults With Relapsed/Refractory Cancers
Sponsor:

Case Comprehensive Cancer Center

Brief Summary:

A personalized cancer medicine approach would address therapy resistance, cancer metastasis, and limited options after standard of care is exhausted in advanced cancer participants. This approach may reduce the barriers to approved therapeutic assignment currently limited to a particular cancer type or patient demographic.

Condition or disease

Refractory Cancer

Relapsed Cancer

Intervention/treatment

Drug Sensitivity Test (DST)

Phase

NA

Detailed Description:

Treatment itself will not be given as part of this trial. The results of the drug sensitivity test (DST) and genomic screening will be used to inform treating physician about participant-specific drug sensitivity or resistance guiding best therapy choices. The physician will decide the most appropriate treatment for each case, with the option to add one or more personalized (assay-guided) drug(s) from the investigational platform. All participants will need to be consented separately for any subsequent investigational treatment if no standard treatment options are available.

Study Type : INTERVENTIONAL
Estimated Enrollment : 36 participants
Masking : NONE
Primary Purpose : SUPPORTIVE_CARE
Official Title : Individualized Treatments in Adults With Relapsed/Refractory Cancers
Actual Study Start Date : 2023-11-20
Estimated Primary Completion Date : 2025-11
Estimated Study Completion Date : 2025-11

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Participants aged 18 years or older at the time of enrollment on this study of any gender, race, or ethnicity.
  • * Patients with suspected or confirmed diagnosis of recurrent or refractory cancer with no curative treatment options.
  • * Participants who have undergone at least two lines of previous therapy.
  • * Participants who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) or who have scheduled or recently had paracentesis or thoracentesis performed.
  • * Participants willing to have a blood draw or buccal swab done for the purposes of genetic testing.
  • * Participants willing to sign informed consent.
Exclusion Criteria
  • * Participants who do not have malignant tissue available and accessible.
  • * Participants for whom the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling.
  • * Participants with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.
Individualized Treatments in Adults With Relapsed/Refractory Cancers

Location Details

NCT06024603

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Florida

Florida International University

Miami, florida, United States, 33199

RECRUITING

United States, Florida

Lerner College of Medicine, Cleveland Clinic Florida

Weston, florida, United States, 33331